ClinicalTrials.gg
RecruitingNCT07745361MODeFIRe-1Updated Nov 5, 2026

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

A Phase 2 interventional study of Oral MRT-2359 and Apalutamide in Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer and Prostate Cancer, sponsored by Monte Rosa Therapeutics, Inc. Recruiting at 14 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Monte Rosa Therapeutics, Inc · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,597 studies in Prostatic Neoplasms with a site in United States — 605 open to participants now, 974 under way, 100 of them phase 3. Prostatic Neoplasms · United States.

Planned enrollment
2,089th of 3,024
25 · median 48
Started
2026
with 175 others
Phase 2
1,063 of 3,597
144 open now
Primary completion
2027-10
later than 525 of 968 live
Registered
3,558th of 3,597
by date

Among the 3,597 studies in Prostatic Neoplasms with a site in United States, this one is the 2,089th largest by planned enrollment of the 3,024 interventional ones that give a count, is one of 176 that started in 2026, is one of 1,063 in phase 2, reaches primary completion later than 525 of the 968 other live ones, and was the 3,558th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

605 of the 3,597 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

600 more — sign in →

All 605 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,597 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer.

Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Read the detailed description

This Phase 2, open-label, multicenter study is designed to assess the efficacy, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of MRT-2359 in combination with apalutamide in patients with castration-resistant prostate cancer.

The primary aim of the study is to assess the PSA response rate of MRT-2359 in combination with apalutamide as determined by PCWG4 criteria.

Secondary aims include further evaluation of safety and tolerability, additional measures of anti-tumor activity, and characterization of the PK profile of MRT-2359 in combination with apalutamide.

03

Conditions studied

  • Castration-Resistant Prostate Cancer (CRPC)
  • Castration-Resistant Prostate Cancer
  • Prostate Cancer
  • Prostate Cancer (Adenocarcinoma)

Keywords

  • MRT-2359
  • apalutamide
  • castration-resistant prostate cancer
  • CRPC
  • androgen receptor mutation
  • AR mutation
  • PSA response
  • androgen receptor inhibitor
  • molecular glue degrader
  • GSPT1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years
  • A predicted of ≥ 3 months and an performance status ≤ 1
  • Have or cytologically confirmed castration-resistant adenocarcinoma of the prostate without small cell histology and with androgen receptor (AR) mutations
  • Have not had prior treatment with more than 1 prior taxane-based chemotherapy regimen for castration-resistant prostate cancer
  • Have no prior treatment with an AR degrader, opevesostat, or similar therapy
  • Has ongoing (chemical or surgical) androgen deprivation with serum testosterone \< 50 ng/dL (\< 1.7 nM)
  • Has received prior treatment with poly(ADP-ribose) polymerase (PARP) inhibitor, if appropriate, or deemed ineligible to receive treatment by the Investigator, or has refused PARP inhibitor treatment
  • Has received prior treatment with at least 1 line of ARPi
  • Have disease measurable per Prostate Cancer Working Group 4 (PCWG4) criteria, with or without by 1.1
  • Be able to provide a tumor for biomarker analysis during the Screening period
  • Have adequate organ function

Exclusion criteria

Exclusion Criteria:

    • Have received prior chemotherapy, definitive radiation, or biological cancer therapy within 21 days before the first dose of study treatment or have any AEs that have failed to recover to baseline

      • Have received prior therapy with a GSPT1 degrader that was discontinued due to an AE
      • Have received prior auto-HCT and have not fully recovered from effects of the last transplant
      • Have received hematopoietic stem cell transplantation within past 6 months and/or have symptoms of
      • Current use of chronic systemic therapy in excess of replacement doses
      • Have clinically active central nervous system involvement and/or carcinomatous meningitis
      • Have a confirmed history of (noninfectious) pneumonitis that required steroids
      • cardiac disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    MRT-2359 + Apalutamide

    Participants with castration-resistant prostate cancer will receive MRT-2359 in combination with apalutamide.

    Drug: Oral MRT-2359 · Drug: Apalutamide

Interventions

  • DrugOral MRT-2359

    Orally administered tablets of MRT-2359

  • Orally administered apalutamide

06

What researchers measure

Primary outcomes

  1. Assess the efficacy of MRT-2359 combined with apalutamide

    Assess the efficacy of MRT-2359 combined with apalutamide using the PSA response rate as determined by PCWG4 criteria in participants with measurable and/or evaluable disease

    Time frame: 14 months

Secondary outcomes

  1. Further evaluation of the safety and tolerability of MRT-2359 administered orally in combination with apalutamide

    Further evaluate the safety and tolerability of MRT-2359 administered orally in combination with apalutamide over a 28-day cycle by the nature, incidence, and severity of all adverse events

    Time frame: 20 months

  2. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    Objective response rate as determined by RECIST 1.1

    Time frame: 20 months

  3. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    Duration of response (DoR) in participants with CR or PR per RECIST 1.1

    Time frame: 20 months

  4. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    Duration of response (DoR) in participants with the best overall response of PSA50 per PCWG4

    Time frame: 20 months

  5. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    Disease control rate (DCR) per RECIST 1.1

    Time frame: 20 months

  6. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    Radiographic progression free survival (PFS)

    Time frame: 20 months

  7. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    PSA progression free survival (PFS)

    Time frame: 20 months

  8. To assess additional measures of the efficacy of MRT-2359 in combination with apalutamide

    Overall survival (OS)

    Time frame: 20 months

  9. To characterize the population pharmacokinetic profile of MRT-2359 in combination with apalutamide

    Peak Plasma Concentration (Cmax)

    Time frame: 20 months

  10. To characterize the population pharmacokinetic profile of MRT-2359 in combination with apalutamide

    Minimum Plasma Concentration (Cmin)

    Time frame: 20 months

  11. To characterize the population pharmacokinetic profile of MRT-2359 in combination with apalutamide

    Area Under the Plasma Concentration-time Curve (AUC)

    Time frame: 20 months

07

Study locations

7 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Oct 2027, 14 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 14 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2026
First posted
Aug 4, 2026
StartActual
Aug 18, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Apr 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • University of Washington Medical Center · Seattle, United StatesNot yet recruiting→Recruiting
  • Lancaster Urology · Lancaster, United StatesNot yet recruiting→Recruiting
  • Virginia Cancer Specialists · Fairfax, United StatesNot yet recruiting→Recruiting
across 3 updates, Oct 8, 2026 – Nov 5, 2026
Show all 3 updates
  1. Nov 5, 2026
    Virginia Cancer Specialists is now Recruiting
  2. Nov 4, 2026
    Lancaster Urology is now Recruiting
    + 1 other change: verification date
  3. Oct 8, 2026
    University of Washington Medical Center is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07745361
Lead sponsor
Monte Rosa Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 4, 2026
Start date
Aug 18, 2026
Primary completion
Oct 2027 (estimated)
Completion
Apr 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Monte Rosa Therapeutics Sponsor
Contact
MRT-2359-002StudyTeam@monterosatx.com
617-865-4792

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion